» Articles » PMID: 15164440

Phenotypic Expression of a Family with Multiple Endocrine Neoplasia Type 2A Due to a RET Mutation at Codon 618

Overview
Journal Br J Surg
Specialty General Surgery
Date 2004 May 28
PMID 15164440
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple endocrine neoplasia type 2A (MEN2A) is caused by missense mutations in the RET proto-oncogene on chromosome 10. This paper reports the phenotypic expression of a family with MEN2A, in which serine substitutes for cysteine at codon 618 in exon 10 of the RET gene. It was first claimed that medullary thyroid cancer (MTC) with this rare mutation led to mild disease; this has recently been updated to intermediate-high risk, based on stratified genetic information.

Methods: The family was mapped over six generations. In 1971 family members were invited to join a screening programme. Genetic testing was started in 1994.

Results: Twenty-two individuals with MTC were identified, 16 by the screening programme. One screened patient had a phaeochromocytoma and four had hyperparathyroidism. At surgery for MTC 12 patients had local tumour metastases and two young patients also had liver metastases. No screened patient died from MTC during a mean observation time of 19 years. Six other family members were diagnosed with MTC by signs and symptoms, five of whom died from MTC.

Conclusion: Because of the great interindividual differences in tumour aggressiveness within the family it is impossible to predict whether an individual gene carrier will have an aggressive MTC or not. This unpredictability is an additional argument, besides those obtained in stratified genetic studies, for operating on gene carriers at young age.

Citing Articles

Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg mutation in an Israeli multicenter study.

Rosenblum R, Hirsch D, Grozinsky-Glasberg S, Benbassat C, Yoel U, Ishay A Front Endocrinol (Lausanne). 2023; 14:1268193.

PMID: 38027168 PMC: 10646927. DOI: 10.3389/fendo.2023.1268193.


RET Proto-Oncogene Variants in Patients with Medullary Thyroid Carcinoma from the Mediterranean Basin: A Brief Report.

Neocleous V, Fanis P, Frangos S, Skordis N, Phylactou L Life (Basel). 2023; 13(6).

PMID: 37374115 PMC: 10304728. DOI: 10.3390/life13061332.


Active Surveillance in Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia.

Prete A, Matrone A, Gambale C, Bottici V, Cappagli V, Romei C Cancers (Basel). 2021; 13(21).

PMID: 34771717 PMC: 8583610. DOI: 10.3390/cancers13215554.


Variability in Medullary Thyroid Carcinoma in L790F Carriers: A Case Comparison Study of Index Patients.

Mathiesen J, Nielsen S, Rasmussen A, Kiss K, Wadt K, Hermann A Front Endocrinol (Lausanne). 2020; 11:251.

PMID: 32411094 PMC: 7198720. DOI: 10.3389/fendo.2020.00251.


Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.

Fanis P, Skordis N, Frangos S, Christopoulos G, Spanou-Aristidou E, Andreou E J Endocrinol Invest. 2018; 41(10):1149-1157.

PMID: 29396759 PMC: 6182349. DOI: 10.1007/s40618-018-0841-0.